Dendrimers improve anticancer efficacy in lung metastasis model

Mar 4th, 2013

Starpharma today announced the results of an animal study which shows that a dendrimer-based formulation of doxorubicin was substantially more efficacious in treating secondary tumours of breast cancer (metastases) in lungs than the drug alone.

Read More

Starpharma Interim Report and Half-year Financial Results

Feb 14th, 2013

Starpharma today released its interim report and financial results for the half-year ended 31 December 2012.

Financial Highlights

  • Reported loss $1.8M (Dec 2011: $4.7 million)
  • R&D tax incentives of $6.8M reported in the half-year
  • Cash position at 31 December 2012 $33.2M
  • R&D tax incentive receivables at 31 December 2012 $8.1M
Read More

Appendix 4C - Quarterly Cashflow Report

Jan 30th, 2013

Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 31 December 2012.

Read More

Herald Sun: Promising shares for the adventurous investor - Small can be bountiful

Jan 6th, 2013

The Herald Sun’s Chief Business Writer John Beveridge investigates some of the best strategies to make money on the stock market and profiles Starpharma as having potential, following the results of its Phase III trial for VivaGel as a treatment for BV:

All is not lost, though, because VivaGel still has potential to become the most effective treatment for the complaint and the company's dendrimer technology has numerous other lucrative applications.

Read More